<DOC>
	<DOCNO>NCT01454440</DOCNO>
	<brief_summary>Patients stable coronary artery disease , undergo PCI mean implantation &gt; 33 mm DES , randomize single-blinded eptifibatide plus unfractioned heparin accord ESPRIT protocol v placebo plus unfractioned heparin .</brief_summary>
	<brief_title>The INtegrilin Plus STenting Avoid Myocardial Necrosis Trial ( INSTANT )</brief_title>
	<detailed_description>BACKGROUND : Despite availability several potent antithrombotic agent , optimal antiplatelet regimen elective patient undergo complex percutaneous coronary intervention still debate . Aim INtegrilin plus STenting Avoid myocardial Necrosis Trial ( INSTANT ) ass safety efficacy routine usage glycoprotein IIb/IIIa inhibitor eptifibatide subject already treat aspirin clopidogrel , undergo implantation least 2 drug-eluting stent lesion , thus identify clinically stable anatomically complex patient subset . DESIGN : This single-blind , placebo-controlled multicenter randomize trial METHODS : Patients stable coronary artery disease , undergo percutaneous coronary intervention ( PCI ) mean implantation &gt; 33 mm DES ( eg two 23-mm DES , one 32-mm one 12-mm DES ) , randomize , administration aspirin clopidogrel ( 600 mg load dose recommend ) , eptifibatide unfractioned heparin accord ESPRIT protocol v placebo unfractioned heparin . Blood draw CK-MB mass , total CK cardiac troponin level take baseline , 6 12 hour post-procedurally . Patients follow clinical event direct visit phone contact 6 month . The primary end-point study rate abnormal post-PCI CK-MB mass value . Secondary end-points : composite cardiac death , non-fatal myocardial infarction ( MI ) , urgent target vessel revascularization ( TVR ) , thrombotic bailout GpIIb/IIIa inhibitor therapy within 180 day , in-hospital , 1-month 6-month major adverse cardiovascular event ( MACE ) , define composite cardiac death , non-fatal MI , urgent TVR . IMPLICATIONS : The INSTANT Study test first time beneficial impact routine GpIIb/IIIa inhibition top double oral antiplatelet treatment clinically stable yet anatomically complex patient undergo DES-implantation . Results single-blind randomized trial provide important insight improve management strategy patient outcomes current DES era .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Eptifibatide</mesh_term>
	<criteria>male female able understand sign witness informed consent , age ≥ 18 year patient stable ( Canadian Cardiovascular Society IIV ) unstable angina pectoris ( recent anginal episode occur &gt; 48 hour procedure [ provide recent CKMB mass level within limit normal ] ) document silent ischemia stable hemodynamic condition ( systolic blood pressure &gt; 100 , heart rate &gt; 40 &lt; 100 ) clinical ECG change suggestive ongoing acute recent ( &lt; 48 hour ) myocardial infarction . female sex childbearing potential age &lt; 18 year ongoing recent episode ( &lt; 48 hour ) unstable coronary artery disease ( include STelevation nonSTelevation acute coronary syndrome ) without normalization CKMB mass level administration GP IIb/IIIa inhibitor previous 2 week , serum creatinine &gt; 2.5 mg/dl &gt; 350 micromols/l ongoing serious bleed bleed diathesis previous stroke last 6 month major surgery within previous 6 week platelet count &lt; 100,000 per mm3 ejection Fraction 30 % know hypersensitivity contraindication aspirin , heparin , clopidogrel sensitivity contrast adequately premedicated hemodynamic instability ( systolic blood pressure &lt; 100 mm Hg ; heart rate &lt; 40 bpm &gt; 100 bpm ; complex ventricular arrhythmia ; atrioventricular block ) require balloon counterpulsation inotropic support simultaneous participation another device drug study ( patient must complete followup phase previous study least 30 day prior enrollment study ) positive clinical history intracranial neoplasia , arteriovenous malformation , aneurysm INR ≥ 2.0 prothrombin time 1.2 time upper limit normality clinically manifest reduce liver function program surgery within one month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Coronary artery disease</keyword>
	<keyword>Eptifibatide</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
	<keyword>stable coronary artery disease</keyword>
	<keyword>percutaneous coronary intervention ( PCI )</keyword>
	<keyword>DES</keyword>
</DOC>